Vimarsana
Biggest News Aggregation in the World

Page 4 - Multiple Sclerosis Relapse News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple Sclerosis Relapse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple Sclerosis Relapse Today - Breaking & Trending Today

Biogen to Pay $900M to Settle Physician Kickback Allegations - Vimarsana News

Biogen to Pay $900M to Settle Physician Kickback Allegations

Former employee/whistleblower to receive $250 million as part of settlement involving three drugs used to treat muscular sclerosis.

Ublituximab Bests Teriflunomide for MS in Two Phase 3 Trials - Vimarsana News

Ublituximab Bests Teriflunomide for MS in Two Phase 3 Trials

Ublituximab is superior to teriflunomide in suppressing multiple sclerosis relapses and lesions on MRI, suggest findings from the phase 3 ULTIMATE I and II trials.

Novel Drug for Relapsing-Remitting MS: New Phase 2 Data - Vimarsana News

Novel Drug for Relapsing-Remitting MS: New Phase 2 Data

The second-generation selective DHODH inhibitor vidofludimus calcium met a phase 2 trial primary endpoint of suppressing new active lesions on MRI and was well tolerated.

No Clear Answers From MS Drug Discontinuation Trial - Vimarsana News

No Clear Answers From MS Drug Discontinuation Trial

The first randomized trial to examine if older adults with multiple sclerosis can discontinue disease-modifying therapy after years of being relapse-free failed to deliver a definitive conclusion.

Novel Drug Tied to Slowed Disease Progression in Relapsing MS - Vimarsana News

Novel Drug Tied to Slowed Disease Progression in Relapsing MS

The novel anti-CD20 monoclonal antibody ublituximab showed greater improvement vs terifulnomide in stabilizing disease progression in relapsing multiple sclerosis in two phase 3 trials.